Recuperaciones y Avisos de Medicamentos para Miembros

A continuación se presentan los recientes retiros y avisos de medicamentos a nivel nacional.

Si está tomando alguno de los siguientes productos:

  • Por favor, hable con su médico inmediatamente para considerar cambiar a un medicamento diferente para su condición.
  • Devuelva el medicamento retirado a su farmacia.
  • Puede ponerse en contacto con su médico si tiene preguntas sobre estos retiros y avisos.

Medication Recalls

  • Ranitidine Tablets, 150 mg and 300 mg, and Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL
    Manufacturer: Amneal Pharmaceuticals, LLC
    Recall Date: 11/08/2019
    Reason: Due to potential N-Nitrosodimethylamine (NDMA) amounts being above levels established by the FDA.
    FDA Notice
  • Ranitidine Tablets 150mg, Ranitidine Capsules 150 mg, Ranitidine Capsules 300 mg and Ranitidine Syrup 15 mg/mLRanitidine Tablets, Capsules, and Syrup
    Manufacturer: Aurobindo Pharma USA, Inc.
    Recall Date: 11/06/2019
    Reason: Due to the detection of Nitrosodimethylamine (NDMA) impurity.
    FDA Notice
  • Ranitidine Syrup (Oral Solution, USP), 15 mg/mL
    Manufacturer: Lannett Company, Inc.
    Recall Date: 10/25/2019
    Reason: Due to levels of N-Nitrosodimethylamine (NDMA) being above the levels recently established by the FDA.
    FDA Notice
  • Ranitidine Tablets & Capsules
    Manufacturer: Dr. Reddy’s Laboratories Ltd.
    Recall Date: 10/23/2019
    Reason: Contamination with N-Nitrosodimethylamine (NDMA) above the levels established by the FDA.
    FDA Notice
  • Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg
    Recall Date: 06/26/2019
    Manufacturer: Macleods Pharmaceuticals, Ltd.
    Reason: Detection of trace amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the interim acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg
    Recall Date: 02/22/2019
    Manufacturer: Macleods Pharmaceuticals, Ltd.
    Reason: Detection of trace amounts of an unexpected impurity (NDEA) above the interim acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
    Recall Date: 01/22/19
    Manufacturer: Torrent Pharmaceuticals Limited
    Reason: Detection of trace amounts of an N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
    FDA Notice 
  • Irbesartan and Irbesartan HCTZ Tablets
    Recall Date: 01/18/2019
    Manufacturer: Prinston Pharmaceutical Inc. dba Solco Healthcare LLC
    Reason: Detection of trace amount of N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA.
    FDA Notice
  • Valsartan and Valsartan-HCTZ Tablets, USP
    Recall Date: 07/18/2018
    Manufacturers: Prinston Pharmaceuticals, and TEVA Pharmaceuticals.
    Reason: It has been found that the recalled products for impurity detected. This may cause unexpected health risks.
    FDA Notice – Prinston Pharmaceuticals
    FDA Notice – TEVA Pharmaceuticals

Medication Notices

  • Lunesta (eszopiclone), Sonata (zaleplon), Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist (zolpidem)
    Notification Date: 04/30/2019
    Certain Prescription Insomnia Medicines: New Boxed Warning – Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake
    FDA Notice